Gerresheimer Glas

What Gerresheimer Glas does

Gerresheimer AG is a Düsseldorf-headquartered, publicly listed German pharmaceutical packaging and drug delivery systems provider founded in 1864. The company operates 39 production sites across 16 countries on three continents with approximately 13,600 employees, producing glass and plastic primary packaging (vials, syringes, ampoules, cartridges, bottles, closures), proprietary drug delivery devices (Gx Inbeneo autoinjectors, Gx InPuls on-body injectors, pen injectors, inhalers), and digital health solutions (Gx InMonit, Gx AdheraLink, Gx Cap with LTE). Its technology stack spans tubular and moulded glass production, injection and blow moulding, cleanroom assembly of combination products, and co-developed platforms with Corning (Velocity Vial), Milliken (LeneX UltraGuard), and others, organized under the tiered Gx Performance Levels architecture (Value, Advance, Elite).

Gerresheimer generates revenue primarily through direct B2B sales of pharmaceutical primary packaging (~81% of FY2024 revenue of ~€2.04 billion), with cosmetics (~12%) and food & beverage (~7%) as secondary segments. Sales are conducted through enterprise field sales teams and major industry trade shows (CPHI, Pharmapack, BIO), with bespoke commercial contracts whose pricing is not publicly disclosed. Key customers include Pfizer, Eli Lilly, and SQ Innovation (FDA-approved Lasix ONYU combination product). The company holds extensive regulatory certifications (FDA, ISO 15378, GMP, EU MDR) across all manufacturing facilities and operates the Advanced Technologies division built on the 2018 Sensile Medical acquisition.

The business is undergoing significant restructuring as of mid-2026 following a BaFin accounting investigation, revenue recognition corrections, leadership transitions (interim CEO Uwe Röhrhoff, new CFO Wolf Lehmann), and a rejected Silgan Holdings takeover bid. Concurrent strategic moves include the announced spin-off of the Moulded Glass business (€735 million revenue, acquired via Bormioli Pharma for €800 million in 2024), Centor Inc. divestiture, Chicago Heights factory closure with offshoring, and continued capacity expansion in Peachtree City (USA), Wertheim (Germany), and Skopje (North Macedonia). Activist investor Active Ownership Fund holds 15.19% and Goldman Sachs disclosed voting rights exceeding 10%, with the company removed from the SDAX index in April 2026.

Name

Gerresheimer Glas

Legal name

Gerresheimer AG

Website

https://gerresheimer.com

Company type

Public

Founded year

1864

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Gerresheimer AG is a German pharmaceutical packaging and drug delivery systems manufacturer producing glass and plastic primary packaging, autoinjectors, on-body injectors, and digital adherence solutions for global pharmaceutical, biotech, and cosmetics companies across 39 production sites in 16 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Packaging

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

Keywords

• Pharmaceutical packaging
• Glass vials syringes
• Drug delivery devices
• Autoinjectors on-body injectors
• Primary packaging solutions

Headquarters

HQ city

Düsseldorf

HQ country

Germany

HQ region

Europe

Offices50 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Primary Packaging Sales: Sale of glass and plastic pharmaceutical primary packaging (vials, syringes, ampoules, cartridges, bottles, closures) to pharmaceutical manufacturers. This is the core revenue driver, representing approximately 81% of total group revenue.
2. Drug Delivery Systems and Devices: Sale of proprietary and contract-manufactured drug delivery devices including autoinjectors, on-body injectors, pen injectors, inhalers, and micro pump systems, as well as development and industrialization services for combination products.
3. Medical and Diagnostic Products: Sale of medical devices and diagnostic products including point-of-care tests, laboratory disposables, and medical devices manufactured under ISO 13485 and MDR compliance.
4. Cosmetics Packaging: Sale of glass and plastic packaging solutions for the cosmetics and personal care industry, representing approximately 12% of group revenue.
5. Food & Beverages Packaging: Sale of glass packaging for food, beverages, nutraceuticals, and vitamin drinks, representing approximately 7% of group revenue.
6. Branded Vial Technology (Corning Partnership): Revenue from branded vial products developed and supplied under the partnership with Corning (Velocity Vial technology), providing premium injectable medication packaging solutions globally.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Gerresheimer AG manufactures and supplies pharmaceutical primary packaging (glass and plastic vials, syringes, ampoules, cartridges, bottles) and proprietary drug delivery devices (autoinjectors, on-body injectors, pen injectors, inhalers). The company also offers device development and contract manufacturing services for combination products, plus digital patient adherence solutions. Approximately 81% of revenue comes from pharma, 12% from cosmetics packaging, and 7% from food & beverage packaging.

Product overview

Gerresheimer is a global systems and solutions provider for the pharma, biotech, and cosmetics industries, operating a broad portfolio of products organized across performance tiers (Gx Value, Advance, Elite, and Choice) for different market segments. The core pharmaceutical primary packaging portfolio includes prefillable syringes (Gx RTF, ClearJect in glass and COP polymer), vials (Gx Elite, EZ-fill Smart, Velocity, COP), ampoules, and cartridges, plus molded glass and plastic containers. Proprietary drug delivery devices include the Gx Inbeneo autoinjector platform, Gx InPuls on-body injector, and pen injectors. A digital solutions layer offers Gx InMonit patient adherence add-on, Gx AdheraLink AI-driven patient communication, Gx Cap smart LTE-connected closure for medication monitoring, and digital therapeutics via Newel Health partnership. The Advanced Technologies division includes Sensile Medical's micro pump technology. The Moulded Glass Powerhouse (8 facilities) was acquired through Bormioli Pharma and is being divested. Cosmetics packaging includes standard lines (Gx Alevio, Ampla, AlevioUltra, Cisio, CyClic, Orbis) plus customized solutions. Recent product launches include LeneX UltraGuard moisture-barrier technology and Gx InMonit smart digital add-on. The company operates over 40 production sites across Europe, Americas, and Asia with approximately 13,600 employees.

Differentiator

Problem solved

Functional benefit

Brands

• Gx: Brand prefix for pharmaceutical primary packaging products including Gx Ampoules, Gx Vials, Gx Syringes, Gx Cartridges, Gx Caps
• Gx Inbeneo
• Gx InMonit
• Gx AdheraLink
• Centor
• Sensile Medical
• Bormioli Pharma
• ClearJect
• LeneX UltraGuard

Products and services

• Gx Elite RTF Vials Ready-to-fill glass vials offering the highest quality standard for sensitive biologics and pharmaceutical formulations, with EZ-fill Smart platform integration. For pharmaceutical manufacturers.
• Gx Elite RTF Syringes High-quality prefillable glass syringes designed for optimal drug stability, smooth delivery, and enhanced patient comfort for sensitive formulations and biologics. For pharmaceutical manufacturers.
• Gx Advance RTF Syringes Prefillable syringes offering efficient fill-finish performance with customizable add-ons, suitable for obesity treatments, vaccines, veterinary and ophthalmological treatments. For pharmaceutical manufacturers.
• ClearJect RTF Syringes Cycloolefin Polymer (COP) syringes with optimal biocompatibility and precision for aesthetic applications and sensitive biologics. Distributed through Gerresheimer's portfolio. For pharmaceutical manufacturers.
• Velocity Vial Gx Advance Vials with Velocity outer coating developed by Corning Inc., reducing friction resistance and minimizing glass defects during fill-finish processes. For pharmaceutical manufacturers.
• Gx Elite COP Vials Cyclic Olefin Polymer vials combining best properties of plastic and glass packaging for liquid pharmaceuticals, with excellent drug compatibility and break resistance. For pharmaceutical manufacturers.
• Gx Ampoules Pharmaceutical ampoules in Type I borosilicate glass, available in Flint and Amber glass with fill volumes from 1 to 50 ml, with various break systems. For pharmaceutical manufacturers.
• Gx Cartridges High-quality glass cartridges in hydrolytic Class I borosilicate glass with fill volumes 1.5 to 3.0 ml, available in EZ-fill Nest & Tub configuration. For dental, insulin, GLP-1 and custom pharmaceutical applications.
• Moulded Glass Packaging Moulded glass packaging including Type I, II, III glass bottles and containers for parenteral, solid oral, and liquid oral pharmaceuticals. For pharmaceutical manufacturers.
• Plastic Primary Packaging Plastic containers and bottle systems for solid oral, liquid oral, ophthalmic, nasal, parenteral and topical applications including containers, dual-chamber systems, dropper bottles, closures, nasal sprays, nebulizers, and accessories. For pharmaceutical manufacturers.
• Clinical Trial Kit Sterile Gx RTF glass vials in EZ-fill Nest & Tub or Tray configuration with matching closures, simplifying and accelerating drug development for clinical phases. For pharmaceutical developers.
• Gx Inbeneo Autoinjector Proprietary autoinjector platform for high-volume, high-viscosity biologics with human-centered design, visual and audible indicators, and adaptability to specific biologic drugs. For pharmaceutical companies developing combination products.
• Gx InPuls On-Body Device On-body injector platform used in FDA-approved combination products (SQ Innovation's Lasix ONYU) for subcutaneous drug delivery in chronic disease management. For pharmaceutical companies.
• Gx Cap Smart Closure Smart medication adherence closure for prescription vials that monitors vial openings via LTE technology and sends SMS reminders when doses are missed, with up to 12-month battery life. For pharmaceutical companies and pharmacies.
• Device Development & Contract Manufacturing Integrated solutions from concept development to finished combination products, including product development, industrialization, contract manufacturing, project management, and quality management. For pharmaceutical and biotech companies.
• Diagnostic & Medical Products Full-service offerings for diagnostics and medical devices including product development, industrialization, contract manufacturing, laboratory disposables, point-of-care tests, and medical devices manufactured under ISO 13485 and MDR compliance. For medical device and diagnostics companies.
• Gx CyClic Cosmetics Packaging Sustainable cosmetics packaging solution with reduced material usage and environmental footprint. For cosmetics and personal care brands.
• Gx Orbis Cosmetics Packaging Premium cosmetics packaging solution in the standard product line for perfume, cosmetic and personal care industries. For cosmetics brands.
• Gx Ampla / Cisio Cosmetics Packaging Standard cosmetics packaging product lines serving the perfume, cosmetic and personal care industries. For cosmetics brands.
• Gx Alevio / AlevioUltra Cosmetics Packaging Standard cosmetics packaging product lines for high-quality glass packaging solutions. For cosmetics brands.
• Digital Therapeutics (via Newel Health partnership) Digital therapy solutions developed in partnership with Newel Health, supporting pharmaceutical and biotech companies in developing digital endpoints and integrated drug+digital solutions. For pharma and biotech companies.

Quantifiable outcome

• LeneX UltraGuard technology reduces moisture ingress into HDPE pharmaceutical packaging by up to 40%.
• +5 more outcomes

Named customers4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature14 records

Partnerships

Seven partnerships are on record, tiered core.

• Newel HealthcoreStrategic or Co-development Partner · 27 May 2026Strategic collaboration to develop integrated digital therapies and drug delivery solutions for pharmaceutical companies. The partnership combines Newel Health's H-Core digital medical device platform and AI-enabled analytics capabilities with Gerresheimer's drug delivery systems and pharmaceutical packaging expertise. The collaboration supports pharma and biotech companies in developing digital endpoints, digital medical devices, and integrated drug+digital solutions without requiring them to build full digital infrastructure internally. Both companies position themselves as strategic partners for pharma firms seeking to embed real-world data and AI into clinical development and commercialization.
• Milliken & CompanycoreTechnology or Integration · 14 May 2026Partnership to develop and supply LeneX UltraGuard moisture-barrier technology for HDPE pharmaceutical packaging. LeneX UltraGuard is an additive system that improves moisture barriers in HDPE packaging by up to 40 percent. Unveiled at Interpack trade fair in Düsseldorf, the technology addresses moisture ingress challenges in pharmaceutical plastic containers, enhancing drug stability and shelf life.
• NuGen Medical DevicescoreStrategic or Co-development Partner · 25 March 2026Collaboration to develop the Prefilled Nozzle platform as an integrated drug-device system. NuGen provides its Ready-to-Fill COP/COC needle-free injection nozzle patent while Gerresheimer Medical Plastics contributes manufacturing expertise and platform development. The system combines prefilled nozzles with reusable auto-injectors. Target: preclinical testing samples by end of 2026, fixed-dose auto-injector launch planned for 2027.
• Corning Inc.coreTechnology or Integration · 26 January 2026Branded vial partnership to develop and supply Gerresheimer-Corning branded vials. Includes the Velocity Vial technology platform expansion globally for filling premium injectable medications. Velocity Vial technology features an advanced outer coating that reduces friction resistance and minimizes glass defects during fill-finish processes, accelerating pharmaceutical manufacturing throughput. The partnership was first established in February 2023.
• SQ InnovationcoreStrategic or Co-development Partner · 13 October 2025FDA-approved Lasix ONYU combination product uses Gerresheimer's Gx InPuls on-body device for subcutaneous furosemide delivery in heart failure patients. SQ Innovation developed the drug-device combination while Gerresheimer provided the proprietary on-body injector platform, marking a regulatory milestone for the Gx InPuls technology.
• Triton fundscoreOthers · 23 May 2024Gerresheimer AG's subsidiary Gerresheimer Glas GmbH signed a purchase agreement with Triton funds to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for approximately EUR 800 million. The acquisition aimed to strengthen Gerresheimer's European presence and create a new Moulded Glass business unit after integration.
• Corning IncorporatedcoreTechnology or Integration · 1 February 2023Partnership to expand the Velocity Vial technology platform globally for filling premium injectable medications. Combines Gerresheimer's pharmaceutical glass manufacturing with Corning's coating technology for improved fill-finish performance.

Scale indicators21 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• AptarGroup: Global supplier of dispensing systems, pumps, valves, and drug delivery interfaces for pharma, beauty, and food. Competes with Gerresheimer's plastic packaging, dropper, and pump businesses and increasingly in inhaled/nasal delivery devices.
• SCHOTT Pharma: Frankfurt-listed subsidiary of SCHOTT AG and the most direct competitor to Gerresheimer in pharma glass primary packaging (vials, syringes, ampoules, cartridges). Competes head-to-head with the Gx portfolio across injectables and biologics containment.
• West Pharmaceutical Services: US-listed leader in elastomeric components, stoppers, syringe plungers, and drug delivery devices (auto-injectors, wearable platforms such as SmartDose). Highly comparable in the drug delivery device and primary containment segments that anchor Gerresheimer's advanced technologies offering.
• DWK Life Sciences: Manufacturer of premium laboratory and pharmaceutical glass packaging, including ampoules, vials, and custom containers. Closely comparable to Gerresheimer's tubular glass and ampoule product lines serving pharma and diagnostics.
• Nipro Corporation: Japanese medical device and pharmaceutical packaging manufacturer producing glass tubing, vials, syringes, and dialysis/artificial organ equipment. Overlaps Gerresheimer's pharma primary packaging portfolio globally.
• Stevanato Group: Italian pharmaceutical containment and drug delivery company offering glass vials, syringes, and proprietary devices (including the Onyx on-body injector platform). Directly comparable to Gerresheimer across high-value injectables and combination products.

Broad incumbents

• SCHOTT AG: Parent of SCHOTT Pharma and a much larger specialty glass, ceramics, and materials group. Overlaps with Gerresheimer's moulded glass, tubing, and pharma containment businesses through SCHOTT Pharma and other divisions.
• Corning Incorporated: Strategic partner of Gerresheimer (Velocity Vial, former tubing owner) and broader manufacturer of pharmaceutical glass, ceramic substrates, and life sciences products. Overlaps in pharma containment but operates across many non-pharma end markets.
• Catalent (Novo Holdings): CDMO with substantial softgel, oral, and injectable fill-finish capabilities, including prefillable syringe and vial filling. Comparable to Gerresheimer's contract manufacturing and combination product industrialization services.
• Becton, Dickinson and Company (BD): Large diversified medical technology company with a substantial pharmaceutical systems business (prefillable syringes, drug delivery, biologics delivery). Competes in select drug delivery categories but covers a much broader medtech portfolio than Gerresheimer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@gerresheimerag
• LinkedInlinkedin.com/company/gerresheimer
• Xx.com/gerresheimer
• Facebookfacebook.com/440473879329920

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gerresheimer Glas